Your browser doesn't support javascript.
loading
The Epidermal Growth Factor, Anaplastic Lymphoma Kinase, and ROS Proto-oncogene 1 Mutation Profile of Non-Small Cell Lung Carcinomas in the Turkish Population: A Single-Center Analysis.
Gün, Eylül; Çakir, Izzetiye Ebru; Ersöz, Hasan; Oflazoglu, Utku; Sertogullarindan, Bünyamin.
Afiliación
  • Gün E; Department of Cellular Pathology, Basildon & Thurrock University Hospital, Mid and South Essex NHS Foundation Trust, Basildon, Essex, United Kingdom.
  • Çakir IE; Department of Pathology, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey.
  • Ersöz H; Department of Thoracic Surgery, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey.
  • Oflazoglu U; Department of Medical Oncology, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey.
  • Sertogullarindan B; Department of Thoracic Diseases, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey.
Thorac Res Pract ; 25(3): 102-109, 2024 Feb 08.
Article en En | MEDLINE | ID: mdl-39162236
ABSTRACT
The management of non-small cell lung carcinomas (NSCLC) has changed with the identification of molecular pathways. We aimed to reveal the 3-year epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) mutation profile in the Turkish population. The histopathological and molecular data of all NSCLC cases from our department between May 2019 and April 2022 were evaluated. Molecular testing was performed in 197 NSCLC cases, and results were obtained in 182 (92.4%) (M/F 144/38, aged 39-86). Of these, 121 were diagnosed with adenocarcinoma, 36 with squamous cell carcinoma, and 25 with NSCLC-not otherwise specified. The EGFR mutation was seen in 21 (11.5%) cases (6 exon 19 deletions, 3 exon 18 [all codon 719], 2 exon 20, 8 exon 21 point mutations, 1 concurrent exon 19 deletion and exon 20 codon 790 M point mutation, and 1 concurrent exon 19 deletion and exon 21 point mutation). The double mutation rate of EGFR was 1.1%. The mean age of these patients was 63.4 (40-79), with 24% of all females (n = 9) and 8.3% of all males (n = 12). The ALK mutation was detected in 6 (3.3%) patients (M/F 4/2, aged 45-82), whereas the ROS1 mutation was detected in 3 (1.7%) (M/F 2/1, aged 40-64). It is well established in the literature that EGFR-activating mutation rates vary depending on regions and ethnic groups. We concluded that the EGFR-activating mutation rates of the Turkish population are similar to the European molecular data instead of the Asian. The ALK and ROS1 mutation rates also seem concordant with the literature.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Thorac Res Pract Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Turquía
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Thorac Res Pract Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Turquía